The Trump administration on Tuesday announced the 15 drugs selected to participate in the newest round of the Medicare Drug Price Negotiation Program, including the high-cost medications Botox and ...
Opportunities in the GLP-1 receptor agonist market include the development of new diabetes and obesity treatments with high ...
Eli Lilly and Co. (NYSE:LLY) released topline results from SURPASS-CVOT, a head-to-head Phase 3 cardiovascular outcomes trial comparing Mounjaro (tirzepatide), a GIP/GLP-1 dual receptor agonist, to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results